ImmuPharma Net Income From Continuing Ops vs Operating Income Analysis

IMM Stock   1.16  0.04  3.57%   
ImmuPharma PLC financial indicator trend analysis is infinitely more than just investigating ImmuPharma PLC recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ImmuPharma PLC is a good investment. Please check the relationship between ImmuPharma PLC Net Income From Continuing Ops and its Operating Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuPharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Net Income From Continuing Ops vs Operating Income

Net Income From Continuing Ops vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ImmuPharma PLC Net Income From Continuing Ops account and Operating Income. At this time, the significance of the direction appears to have strong relationship.
The correlation between ImmuPharma PLC's Net Income From Continuing Ops and Operating Income is 0.79. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Operating Income in the same time period over historical financial statements of ImmuPharma PLC, assuming nothing else is changed. The correlation between historical values of ImmuPharma PLC's Net Income From Continuing Ops and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of ImmuPharma PLC are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Net Income From Continuing Ops i.e., ImmuPharma PLC's Net Income From Continuing Ops and Operating Income go up and down completely randomly.

Correlation Coefficient

0.79
Relationship DirectionPositive 
Relationship StrengthSignificant

Net Income From Continuing Ops

Operating Income

Operating Income is the amount of profit realized from ImmuPharma PLC operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of ImmuPharma PLC is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.
Most indicators from ImmuPharma PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ImmuPharma PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuPharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
The current year's Selling General Administrative is expected to grow to about 1.7 M, whereas Tax Provision is forecasted to decline to (522 K).
 2021 2022 2023 2024 (projected)
Interest Expense2.4M1.5M2.0K1.9K
Depreciation And Amortization114.1K117.6K37.6K35.7K

ImmuPharma PLC fundamental ratios Correlations

-0.30.030.99-0.930.350.920.17-0.470.590.92-0.19-0.320.11-0.160.370.96-0.210.650.11-0.30.22-0.130.40.16-0.19
-0.30.55-0.380.26-0.52-0.27-0.1-0.18-0.31-0.270.610.74-0.080.410.43-0.30.58-0.31-0.150.33-0.04-0.03-0.45-0.350.54
0.030.55-0.080.12-0.65-0.120.220.170.12-0.120.740.730.170.60.76-0.080.75-0.180.470.730.110.53-0.25-0.710.74
0.99-0.38-0.08-0.920.380.910.21-0.460.560.91-0.24-0.370.11-0.180.240.95-0.260.620.1-0.360.2-0.160.420.21-0.24
-0.930.260.12-0.92-0.55-1.00.060.65-0.46-1.00.390.450.190.41-0.35-0.960.41-0.760.130.42-0.090.28-0.41-0.440.37
0.35-0.52-0.650.38-0.550.58-0.59-0.430.330.58-0.96-0.94-0.18-0.95-0.10.54-0.970.75-0.42-0.710.21-0.590.450.81-0.77
0.92-0.27-0.120.91-1.00.58-0.1-0.630.481.0-0.42-0.47-0.19-0.440.380.97-0.430.81-0.13-0.450.1-0.30.440.46-0.38
0.17-0.10.220.210.06-0.59-0.10.41-0.15-0.10.560.380.040.68-0.23-0.090.55-0.40.50.25-0.340.40.11-0.470.43
-0.47-0.180.17-0.460.65-0.43-0.630.41-0.07-0.630.310.230.140.43-0.22-0.60.31-0.380.370.21-0.120.250.1-0.540.34
0.59-0.310.120.56-0.460.330.48-0.15-0.070.48-0.26-0.340.42-0.10.40.6-0.280.450.21-0.130.52-0.130.11-0.22-0.14
0.92-0.27-0.120.91-1.00.581.0-0.1-0.630.48-0.42-0.47-0.19-0.440.380.97-0.430.81-0.13-0.450.1-0.30.440.46-0.38
-0.190.610.74-0.240.39-0.96-0.420.560.31-0.26-0.420.970.210.920.28-0.370.99-0.590.440.65-0.130.54-0.35-0.790.83
-0.320.740.73-0.370.45-0.94-0.470.380.23-0.34-0.470.970.120.860.32-0.450.97-0.610.30.68-0.150.5-0.49-0.720.79
0.11-0.080.170.110.19-0.18-0.190.040.140.42-0.190.210.120.280.030.070.19-0.210.30.220.750.14-0.22-0.470.19
-0.160.410.6-0.180.41-0.95-0.440.680.43-0.1-0.440.920.860.280.08-0.380.91-0.710.440.63-0.090.49-0.42-0.880.71
0.370.430.760.24-0.35-0.10.38-0.23-0.220.40.380.280.320.030.080.390.280.420.140.30.250.16-0.06-0.240.3
0.96-0.3-0.080.95-0.960.540.97-0.09-0.60.60.97-0.37-0.450.07-0.380.39-0.390.77-0.05-0.40.29-0.260.390.34-0.34
-0.210.580.75-0.260.41-0.97-0.430.550.31-0.28-0.430.990.970.190.910.28-0.39-0.60.470.71-0.150.62-0.39-0.780.82
0.65-0.31-0.180.62-0.760.750.81-0.4-0.380.450.81-0.59-0.61-0.21-0.710.420.77-0.6-0.17-0.630.1-0.40.640.58-0.42
0.11-0.150.470.10.13-0.42-0.130.50.370.21-0.130.440.30.30.440.14-0.050.47-0.170.4-0.090.740.19-0.550.7
-0.30.330.73-0.360.42-0.71-0.450.250.21-0.13-0.450.650.680.220.630.3-0.40.71-0.630.40.110.76-0.62-0.630.51
0.22-0.040.110.2-0.090.210.1-0.34-0.120.520.1-0.13-0.150.75-0.090.250.29-0.150.1-0.090.11-0.22-0.16-0.17-0.13
-0.13-0.030.53-0.160.28-0.59-0.30.40.25-0.13-0.30.540.50.140.490.16-0.260.62-0.40.740.76-0.22-0.28-0.440.54
0.4-0.45-0.250.42-0.410.450.440.110.10.110.44-0.35-0.49-0.22-0.42-0.060.39-0.390.640.19-0.62-0.16-0.280.35-0.09
0.16-0.35-0.710.21-0.440.810.46-0.47-0.54-0.220.46-0.79-0.72-0.47-0.88-0.240.34-0.780.58-0.55-0.63-0.17-0.440.35-0.73
-0.190.540.74-0.240.37-0.77-0.380.430.34-0.14-0.380.830.790.190.710.3-0.340.82-0.420.70.51-0.130.54-0.09-0.73
Click cells to compare fundamentals

ImmuPharma PLC Account Relationship Matchups

ImmuPharma PLC fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets5.8M10.9M6.0M4.0M2.7M2.6M
Other Current Liab104.3K110.7K158.8K200.0K768.5K806.9K
Total Current Liabilities531.9K1.3M1.6M1.5M1.7M1.4M
Total Stockholder Equity5.3M9.7M4.4M2.5M1.1M1.0M
Net Debt(1.3M)(5.2M)(1.6M)(667.7K)(208.5K)(218.9K)
Retained Earnings(40.2M)(46.0M)(56.6M)(61.1M)(64.1M)(60.9M)
Cash1.4M5.9M1.6M667.8K208.5K198.1K
Non Current Assets Total2.2M3.5M2.7M1.6M1.4M1.4M
Non Currrent Assets Other1.5M2.6M1.8M772.1K(1.0)(1.05)
Cash And Short Term Investments1.4M5.9M1.6M667.8K208.5K198.1K
Common Stock Total Equity13.3M13.9M16.7M25.0M28.8M30.2M
Common Stock Shares Outstanding153.5M200.2M251.2M302.9M362.0M380.1M
Liabilities And Stockholders Equity5.8M10.9M6.0M4.0M2.7M2.6M
Other Current Assets2.2M1.6M1.7M1.5M1.1M1.3M
Other Stockholder Equity27.3M27.2M27.2M28.8M29.3M30.8M
Total Liab531.9K1.3M1.6M1.5M1.7M1.7M
Total Current Assets3.6M7.4M3.3M2.3M1.3M1.3M
Common Stock16.7M25.0M28.5M29.0M29.8M31.3M
Short Long Term Debt Total26.8K641.8K700.0111.099.994.91
Property Plant And Equipment Net206.7K411.6K353.0K389.7K102.1K181.9K
Accounts Payable329.7K418.1K1.2M1.1M776.2K760.8K
Net Receivables709.1K481.9K1.1M166.3K685.7K950.7K
Property Plant And Equipment Gross206.7K411.6K1.1M1.3M192.3K280.6K
Accumulated Other Comprehensive Income5.0M6.8M8.7M9.3M6.0M6.3M
Short Term Debt26.8K641.8K700.0111.099.994.91
Intangible Assets479.0K484.0K477.6K473.9K447.6K477.8K
Property Plant Equipment164.7K206.7K411.6K353.0K405.9K426.2K
Current Deferred Revenue(175.4K)(201.0K)(427.7K)(380.1K)(437.1K)(458.9K)
Non Current Liabilities Total22.5K531.9K1.3M1.2M1.5M0.0
Net Tangible Assets5.2M9.6M3.9M2.5M2.8M5.2M
Short Long Term Debt98.3K26.8K641.8K700.0111.00.0
Capital Surpluse18.7M27.3M27.2M27.2M31.3M25.6M
Net Invested Capital5.3M10.3M4.4M2.5M1.1M1.0M
Net Working Capital3.0M6.2M1.8M887.6K(321.9K)(305.8K)
Capital Stock16.7M25.0M28.5M29.0M29.8M26.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in ImmuPharma Stock

Balance Sheet is a snapshot of the financial position of ImmuPharma PLC at a specified time, usually calculated after every quarter, six months, or one year. ImmuPharma PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ImmuPharma PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ImmuPharma currently owns. An asset can also be divided into two categories, current and non-current.